Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FDA: friend or foe?

T S Lewis1

  • 1Medical Device Consultancy, Cardiff, UK. trevor@lewlink.demon.co.uk

Medical Device Technology
|October 4, 1996
PubMed
Summary
This summary is machine-generated.

Delays in U.S. Food and Drug Administration (FDA) product approvals are harming the medical device market by reducing investment and slowing innovation. The FDA is working to improve its processes to address these critical issues.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Reply to Vargas: Is Performance Status Enough to Decide the Palliative Radiotherapy Schedule in Lung Cancer?

Clinical oncology (Royal College of Radiologists (Great Britain))·2021
Same author

Palliative Lung Radiotherapy: Higher Dose Leads to Improved Survival?

Clinical oncology (Royal College of Radiologists (Great Britain))·2020
Same author

Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells.

Leukemia·2011
Same author

Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells.

Journal of immunology (Baltimore, Md. : 1950)·2001
Same author

Mitotic phosphorylation of Golgi reassembly stacking protein 55 by mitogen-activated protein kinase ERK2.

Molecular biology of the cell·2001
Same author

Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry.

Molecular cell·2001

Area of Science:

  • Medical Device Market Analysis
  • Regulatory Science
  • Health Economics

Background:

  • U.S. Food and Drug Administration (FDA) product approval delays negatively impact the medical device market.
  • Reduced investment returns and diminished industry confidence in FDA procedures hinder new product introductions.
  • Market growth potential is threatened by these systemic issues.

Purpose of the Study:

  • To examine the background of FDA approval delays and their market impact.
  • To describe the FDA's initiatives to address procedural shortcomings.
  • To provide insights into the challenges facing the US medical device sector.

Main Methods:

  • Literature review of FDA approval processes and market data.
  • Analysis of industry confidence and investment trends.

Related Experiment Videos

  • Examination of FDA's reform efforts.

    • Main Results:

    • Significant delays in FDA approvals have been identified as a primary cause of market weakening.
    • Erosion of industry confidence is linked to procedural inefficiencies.
    • New product pipelines are suffering, impacting future market growth.

    Conclusions:

    • FDA approval delays pose a substantial threat to the US medical device market's vitality.
    • Industry confidence and investment are crucial for sustained market growth.
    • FDA's procedural reforms are essential for market recovery and innovation.